54 results
8-K
EX-99.1
ABOS
Acumen Pharmaceuticals Inc
26 Mar 24
Results of Operations and Financial Condition
7:42am
expectations. Beyond favorable safety results, our study confirmed near-maximal target engagement of abeta oligomers, significant plaque reduction … , ALTITUDE-AD, in the first half of 2024 to investigate the clinical efficacy, safety and tolerability of sabirnetug for the treatment of early
8-K
EX-99.1
dp08f2ykb0m9tq kmit
19 Mar 24
Corporate Presentation March 2024 1
8:05am
8-K
EX-99.1
798bp1mz36p
12 Jan 24
Corporate Presentation January 2024 1
8:42am
8-K
EX-99.1
6d0j a86j
8 Jan 24
Regulation FD Disclosure
8:33am
8-K
EX-99.1
n7un1hlk3hu
4 Dec 23
Corporate Presentation December 2023 1
7:45am
8-K
EX-99.1
qblv0 x2zf9bnewcggiv
13 Nov 23
Corporate Presentation November 2023 1
5:10pm
8-K
EX-99.1
3gq9bbj1tln5i8exfgg4
13 Nov 23
Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights
7:20am
8-K
EX-99.2
ml2h786scohp
8 Aug 23
Acumen Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Highlights
7:33am
8-K
EX-99.1
v1n7q88opkwllf4
8 Aug 23
Acumen Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Highlights
7:33am
424B5
1fogw97 1ufl0jdf
20 Jul 23
Prospectus supplement for primary offering
4:11pm
424B5
uf3 udbi31z4ugq5lh
17 Jul 23
Prospectus supplement for primary offering
4:49pm
8-K
EX-99.2
7jot18kpk94
17 Jul 23
Acumen Pharmaceuticals Presents Positive Topline Results from First-in-Human
6:06am
8-K
EX-99.1
i26 o8zy9o8xq94
17 Jul 23
Acumen Pharmaceuticals Presents Positive Topline Results from First-in-Human
6:06am